Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial.
Jia H, Mai J, Wu M, Chen H, Li X, Li C, Liu J, Liu C, Hu Y, Zhu X, Jiang X, Hua B, Xia T, Liu G, Deng A, Liang B, Guo R, Lu H, Wang Z, Chen H, Zhang Z, Zhang H, Niu J, Ding Y.
Jia H, et al. Among authors: wu m.
BMC Med. 2023 Mar 16;21(1):98. doi: 10.1186/s12916-023-02814-w.
BMC Med. 2023.
PMID: 36927420
Free PMC article.
Clinical Trial.